Trimebutine
| Clinical data | |
|---|---|
| Trade names | Debridat, Recutin, Polybutin, others |
| AHFS/Drugs.com | International Drug Names |
| ATC code | |
| Physiological data | |
| Agonists | opioid receptors |
| Antagonists | mAChR, sodium channels |
| Pharmacokinetic data | |
| Metabolites | nortrimebutine, N-didesmethyltrimebutine, 2-dimethylamino-2-phenylbutan-1-ol, 2-methylamino-2-phenylbutan-1-ol, 2-amino-2-phenylbutan-1-ol |
| Elimination half-life | 2.77 h (for oral dose 200 mg) |
| Excretion | renal, fecal |
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| PubChem SID | |
| ChemSpider | |
| UNII | |
| ChEBI | |
| ChEMBL | |
| CompTox Dashboard (EPA) | |
| ECHA InfoCard | 100.049.354 |
| Chemical and physical data | |
| Formula | C22H29NO5 |
| Molar mass | 387.476 g·mol−1 |
| 3D model (JSmol) | |
| Density | 1.1±0.1 g/cm³ g/cm3 |
| Boiling point | 457.9 °C (856.2 °F) at 760 mmHg |
| |
| |
| (what is this?) (verify) | |
Trimebutine is a drug with antimuscarinic and very weak mu opioid agonist effects. It is used for the treatment of irritable bowel syndrome and other gastrointestinal disorders. It is sometimes combined with simethicone as a combination drug. Trimebutine is formulated as a tablet or granules for oral suspension.